MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.

Merck made a nonbinding offer of over $3 billion for MoonLake, whose lead drug is in Phase 3 trials for arthritis and skin disorders. Investor pressure is rising on Merck as Keytruda nears patent expiration, Gardasil sales fall in China, and Winrevair growth underperforms.

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Dollar General Corp. DG to report quarterly earnings at $1.48 per share on revenue of $10.31 billion before the opening bell, according to data ...